Corsair Pharma is a private biopharmaceutical company focused on developing prodrugs of treprostinil for treatment of PAH. Its core product is a once-daily transdermal patch intended to provide continuous and consistent blood levels of treprostinil comparable to an infusion pump. The patch delivers an inactive prodrug designed to cross the skin, enter the bloodstream, and convert rapidly to treprostinil in the liver. The company is focused on improving the therapeutic profile of medications and providing treatment options for patients. Led by Bobby Singh, Ph.D., President, CEO and Director, Corsair is advancing the patch through clinical development. The company recently completed a Series B financing to support clinical advancement of its program.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2023